Some IDO1 inhibitors alone have shown only moderate therapeutic efficacies in animal models of PC,45, 46, 47 the exploration of new combination therapies is a promising strategy to promote IDO1‐based therapies from bench to bedside. This evidence concerns the gene IDO1 and pachyonychia congenita.